Research projects
Start of main content
Towards the improvement of diagnosis and treatment in Congenital Dyserythropoyetic Anaemias
18th national competition for scientific and technical research
Rare diseases
Senior Researcher : María del Carmen Sánchez Fernández
Research Centre or Institution : Instituto de Investigación contra la Leucemia Josep Carreras (IJC). Barcelona.
Abstract
Congenital dyserythropoietic anaemia (CDA) is a heterogeneous group of hematological disorders characterized by anaemia and distinct morphological abnormalities of erythroid precursors in the bone marrow. Patients with CDA present congenital and chronic anaemia of variable degree with a reticulocytosis not corresponding to the degree of anaemia (ineffective erythropoiesis), jaundice and frequently splenomegaly and/or hepatomegaly. Morbidity in CDA I, CDAII and other CDA patients that require continuous blood transfusions may be important due to iron overload complications that can be fatal if untreated.
Five classical types of CDAs (I-II-III-IV and XLTDA) have been defined on the basis of bone marrow morphology. CDA type II is the most common and well-defined form among CDAs. This working classification is nowadays still used in clinical practice. However, the identification of the mutated genes involved in the majority of CDA subgroups will improve the diagnostic possibilities and will allow a better classification of CDA patients, since at present, in many cases a final diagnosis is not achieved. On the other hand, there are several families that fulfill the general definition of CDAs, but do not conform to any of the classical CDA variants. Although several studies about molecular genetics and genotype-phenotype correlation have been performed in this field, the pathophysiology of CDAs is still an unsolved issue. Beyond to achieve a definitive diagnosis, knowing the genetic basis of CDA patients is valuable also for unravelling the pathophysiology of these disorders, as well as for guiding treatment (depending of the type of CDA, different treatments have been established).
The project is being carried out by 2 international teams that are world-wide recognized as experts in Congenital Dyserythropoietic Anaemia (CDA) and has the direct support of 2 patient associations (ADISCON and APU).
Scientific Production |
|
---|---|
Magazine Articles | 4 |
Communications at national conferences | 7 |
Communications at international conferences | 15 |
- Activities related
- Projects related
- News related
- Publications related
-
30
Jan
2020
International Symposium Understanding and reprogramming developmental visual disorders: from anophthalmia to cortical impairments Madrid, Thursday and Friday, 30 and 31 January 2020, 9:30 hours
-
8
Apr
2024
Panel Discussion Mundo de las prótesis, los nuevos materiales, sus complicaciones y su futuro Madrid , Lunes, 8 de abril 2024. 17.00 horas
-
23
Apr
2024
Session Situación actual de las Enfermedades Raras en España Madrid, Martes, 23 de abril de 2024, 10:00 horas
- Phenotyping of animal models of rare diseases with visual disability 2020 Senior Researcher : Lluís Montoliu José Research Centre or Institution : Centro Nacional de Biotecnología (CNB). CSIC. Madrid
- The neuronal glycine transporter GlyT2 in herplexia: a glycinergic pathology of development 2020 Senior Researcher : Beatriz López Corcuera Research Centre or Institution : Centro de Biología Molecular Severo Ochoa. CSIC - UAM
- Serum markers in patients with congenital melanocytic nevi: clinicopathological and genetic correlation 2020 Senior Researcher : Pedro Redondo Bellón Research Centre or Institution : Clínica Universidad de Navarra. Pamplona
End of main content